CN101568833B - 使用MR-proADM的糖尿病诊断和风险分级 - Google Patents

使用MR-proADM的糖尿病诊断和风险分级 Download PDF

Info

Publication number
CN101568833B
CN101568833B CN200780041709.4A CN200780041709A CN101568833B CN 101568833 B CN101568833 B CN 101568833B CN 200780041709 A CN200780041709 A CN 200780041709A CN 101568833 B CN101568833 B CN 101568833B
Authority
CN
China
Prior art keywords
diabetes
use according
proadm
marker
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200780041709.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN101568833A (zh
Inventor
A·博格曼
N·莫根塔勒
J·帕帕索提里奥
J·斯塔克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BRAHMS GmbH
Original Assignee
BRAHMS GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BRAHMS GmbH filed Critical BRAHMS GmbH
Priority to CN201410442798.5A priority Critical patent/CN104198735B/zh
Publication of CN101568833A publication Critical patent/CN101568833A/zh
Application granted granted Critical
Publication of CN101568833B publication Critical patent/CN101568833B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200780041709.4A 2006-11-08 2007-11-08 使用MR-proADM的糖尿病诊断和风险分级 Active CN101568833B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410442798.5A CN104198735B (zh) 2006-11-08 2007-11-08 使用MR‑proADM的糖尿病诊断和风险分级

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006052916A DE102006052916A1 (de) 2006-11-08 2006-11-08 Diagnose und Risikostratifizierung von Diabetes mellitus mittels MR-proADM
DE102006052916.2 2006-11-08
PCT/DE2007/002018 WO2008055491A2 (de) 2006-11-08 2007-11-08 Diagnose und risikostratifizierung von diabetes mellitus mittels mr-proadm

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410442798.5A Division CN104198735B (zh) 2006-11-08 2007-11-08 使用MR‑proADM的糖尿病诊断和风险分级

Publications (2)

Publication Number Publication Date
CN101568833A CN101568833A (zh) 2009-10-28
CN101568833B true CN101568833B (zh) 2014-09-10

Family

ID=39277540

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200780041709.4A Active CN101568833B (zh) 2006-11-08 2007-11-08 使用MR-proADM的糖尿病诊断和风险分级
CN201410442798.5A Active CN104198735B (zh) 2006-11-08 2007-11-08 使用MR‑proADM的糖尿病诊断和风险分级

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410442798.5A Active CN104198735B (zh) 2006-11-08 2007-11-08 使用MR‑proADM的糖尿病诊断和风险分级

Country Status (7)

Country Link
US (2) US20100035275A1 (enExample)
EP (1) EP2097748B1 (enExample)
JP (2) JP5275247B2 (enExample)
CN (2) CN101568833B (enExample)
DE (1) DE102006052916A1 (enExample)
ES (1) ES2393262T3 (enExample)
WO (1) WO2008055491A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906857B2 (en) * 2005-12-01 2014-12-09 B.R.A.H.M.S. Gmbh Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
AU2007233320B2 (en) 2006-04-04 2013-12-12 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
DE102007009751A1 (de) 2007-02-28 2008-09-04 B.R.A.H.M.S Aktiengesellschaft Verfahren zur selektiven Bestimmung von Procalcitonin 1-116 für diagnostische Zwecke sowie Antikörper und Kits zur Durchführung eines solchen Verfahrens
JP5711131B2 (ja) * 2008-10-07 2015-04-30 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 最初の有害事象の予測のためのバイオマーカー
EP2180322A1 (en) * 2008-10-22 2010-04-28 BRAHMS Aktiengesellschaft Prognostic biomarkers for the progression of primary chronic kidney disease
US20110262939A1 (en) * 2008-10-31 2011-10-27 B.R.A.H.M.S Gmbh Methods and assays for classifying foodstuff and/or beverage and/or diet and/or nutrition regimen and/or medicament in view of an effect on the cardiovascular system
EP2356451A1 (en) * 2008-10-31 2011-08-17 B.R.A.H.M.S GmbH In vitro-method for the diagnosis, prognosis, monitoring and therapy follow-up of disorders associated with the metabolic syndrome, a cardiovascular disease and/or insulin resistance
WO2010054810A1 (en) * 2008-11-11 2010-05-20 B.R.A.H.M.S Ag Prognosis and risk assessment in patients suffering from heart failure by determining the level of adm and bnp
US8450069B2 (en) 2009-06-08 2013-05-28 Singulex, Inc. Highly sensitive biomarker panels
EP2470910B1 (en) * 2009-08-28 2017-01-11 B.R.A.H.M.S GmbH Procalcitonin for the prognosis of adverse events
RU2618437C2 (ru) * 2010-11-01 2017-05-03 Б.Р.А.Х.М.С Гмбх Оценка прогноза и риска пациентов с неспецифическими жалобами
CN105148269A (zh) * 2011-02-21 2015-12-16 菲布他丁有限合伙公司 治疗和诊断疾病的方法
EP2533052A1 (en) * 2011-06-07 2012-12-12 B.R.A.H.M.S GmbH Diagnostic use of proSomatostatin
CN104714020B (zh) * 2013-12-12 2016-05-25 张曼 尿液内源性α胰蛋白酶抑制剂重链H4在2型糖尿病合并冠心病中的应用
WO2017089474A1 (en) * 2015-11-27 2017-06-01 Brahms Gmbh MR-proADM AS MARKER FOR THE EXTRACELLULAR VOLUME STATUS OF A SUBJECT
US20190178894A1 (en) * 2016-08-09 2019-06-13 B.R.A.H.M.S Gmbh Histones and/or proadm as markers indicating an adverse event
CN109564226A (zh) * 2016-08-09 2019-04-02 B.R.A.H.M.S 有限公司 作为指示器官功能障碍的标志物的组蛋白和/或proADM
EP3438668A1 (en) * 2017-08-04 2019-02-06 B.R.A.H.M.S GmbH Diagnosis and risk stratification of fungal infections
EP3682247B1 (en) * 2017-09-13 2022-02-09 B.R.A.H.M.S GmbH Proadrenomedullin as a marker for abnormal platelet levels
WO2019098351A1 (ja) * 2017-11-17 2019-05-23 学校法人東海大学 糖尿病合併症用マーカー

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997007214A1 (en) * 1995-08-18 1997-02-27 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Functional role of adrenomedullin (am) and the gene-related product (pamp) in human pathology and physiology

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19847690A1 (de) * 1998-10-15 2000-04-20 Brahms Diagnostica Gmbh Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen
US6756783B2 (en) * 1999-06-01 2004-06-29 Merlin Technology, Inc Multi-frequency boring tool locating system and method
ATE313802T1 (de) * 1999-09-10 2006-01-15 Us Gov Health & Human Serv Bestimmung von adrenomedullin-bindenden proteinen
DE10316583A1 (de) * 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
JP2007523844A (ja) * 2003-04-25 2007-08-23 ジェノバ・リミテッド 心臓血管障害において減少する分泌ポリペプチド種
EP1619505B1 (en) * 2004-07-22 2008-04-16 BRAHMS Aktiengesellschaft Method for the diagnosis of critically ill patients
GB2418995B (en) * 2004-09-29 2006-08-16 Bookham Technology Plc Apodised binary grating
FI20050011A7 (fi) * 2005-01-05 2006-07-06 Oy Jurilab Ltd Menetelmä ja testipakkaus tyypin 2 diabetes mellituksen riskin havaitsemiseksi

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997007214A1 (en) * 1995-08-18 1997-02-27 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Functional role of adrenomedullin (am) and the gene-related product (pamp) in human pathology and physiology

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Jerzy Beltowski ET AL..ADRENOMEDULLIN – WHAT DO WE KNOW 10 YEARS SINCE ITS DISCOVERY?.《POLISH JOURNAL OF PHARMACOLOGY》.2004,第56卷第5-27页. *
NILS G. MORGENTHALER ET AL..Measurement of Midregional Proadrenomedullin in Plasma with an Immunoluminometric Assay.《CLINICAL CHEMISTRY》.2005,第51卷(第10期),第1824页. *

Also Published As

Publication number Publication date
JP5275247B2 (ja) 2013-08-28
DE102006052916A1 (de) 2008-05-15
EP2097748A2 (de) 2009-09-09
CN104198735B (zh) 2018-01-30
HK1203090A1 (en) 2015-10-16
JP2013047689A (ja) 2013-03-07
CN101568833A (zh) 2009-10-28
WO2008055491A3 (de) 2008-08-21
HK1137805A1 (en) 2010-08-06
WO2008055491A2 (de) 2008-05-15
CN104198735A (zh) 2014-12-10
JP2010509575A (ja) 2010-03-25
EP2097748B1 (de) 2012-08-08
US20100035275A1 (en) 2010-02-11
US20160169912A1 (en) 2016-06-16
ES2393262T3 (es) 2012-12-19

Similar Documents

Publication Publication Date Title
CN101568833B (zh) 使用MR-proADM的糖尿病诊断和风险分级
EP2095107B1 (en) Methods for risk assignment
CN102449486B (zh) 在患有呼吸困难的对象中检测细菌感染
US20100086944A1 (en) Methods and Compositions for Diagnosis and Prognosis of Renal Artery Stenosis
EP2376919B1 (en) Combined natriuretic peptide assays
CN101646945A (zh) 利用CT-proET-1与NT-proBNP的组合进行急性冠状动脉综合征的诊断和风险分层
CN107064525A (zh) 用于测定患有心脏病或被怀疑发生或患有心脏病的患者中的氨基末端proANP的方法
EP2425255A1 (en) Means and methods for diagnosing a heart failure associated kidney damage in individuals in need of a suitable therapy
CN102203608B (zh) 用于与代谢综合征、心血管疾病和/或胰岛素抗性相关的病症的诊断、预后、监测和治疗追踪的体外方法
US20110263438A1 (en) Diagnosis and complication risk assessment of pancreatic diabetes using procalcitonin
JP4734306B2 (ja) ナトリウム利尿ペプチドおよび胎盤増殖因子／可溶性ｖｅｇｆ受容体を用いた、妊婦での心疾患に関連した心機能不全と胎盤関連心機能不全とを区別するための方法
DK2596010T3 (en) SIGNAL biomarkers
US20110081725A1 (en) Assessment of complications of patients with type 1 diabetes
HK1137805B (en) Diagnosis and risk assessment of pancreatic diabetes using mr-proadm
HK1203090B (en) Diagnosis and risk assessment of pancreatic diabetes using mr-proadm
Alan et al. Use of biomarkers in evaluation of patients with heart failure
Indumathi et al. A review on application of biomarkers in heart failure
WO2025133235A1 (en) Adm-gly as marker for early predicting sepsis
Haase et al. Novel Biomarkers of Acute Cardiorenal Disease
WO2023208993A1 (en) Biomarkers of diabetic nephropathy
HK1167273B (en) Detection of bacterial infections in subjects suffering from dyspnea
WO2010018123A1 (en) Retinol binding protein 4 as a marker of peripheral insulin resistance in type 1 diabetes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1137805

Country of ref document: HK

C14 Grant of patent or utility model
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: German Hennings Dov

Applicant after: BRAHMS AG

Address before: German Hennings Dov

Applicant before: Brahms AG

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: BRAHMS AG TO: BRAHMS CO., LTD.

GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1137805

Country of ref document: HK